A Multi-center Randomized Control Cross-over Study to Evaluate the Safety and Effectiveness of Dayspring Active Wearable Compression Device vs. an Advanced Pneumatic Compression Device for Treating Breast Cancer Related Lymphedema
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 50
- 试验地点
- 4
- 主要终点
- Arm Volume Maintenance or Improvement
研究概览
简要总结
To evaluate the Dayspring Active Wearable Compression Device in contrast to an advanced pneumatic compression device (APCD)
详细描述
A Multi-center Randomized Control Single Cross-over Study to Evaluate the Safety and Effectiveness of Dayspring Active Wearable Compression Device vs. an Advanced Pneumatic Compression Device for Treating Breast Cancer Related Lymphedema. To evaluate the Dayspring Active Wearable Compression Device in contrast to an advanced pneumatic compression device (APCD) in a multi-centered setting to evaluate volume, quality of life, safety, adherence, and preference.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males and females ≥ 18 years of age
- •Willing to sign the informed consent and deemed capable of following the study protocol
- •Subjects must have a diagnosis of primary or secondary unilateral upper extremity edema
排除标准
- •Individuals with a history or presence of a systemic disorder or condition that could place the subject at increased risk from sequential compression therapy
- •Inability or unwillingness to participate in all aspects of study protocol and/or inability to provide informed consent
- •Subjects with exam results that would prevent safe and effective use of the study device (cellulitis, open-wounds, healing-wounds, etc.)
- •Subjects must not have any diagnosed cognitive or physical impairment that would interfere with use of the device
- •Diagnosis of lipedema
- •Diagnosis of active or recurrent cancer (< 3 months since completion of chemotherapy, radiation therapy or primary surgery for the cancer)
- •Diagnosis of Acute infection (in the last four weeks)
- •Diagnosis of acute thrombophlebitis (in last 6 months)
- •Diagnosis of pulmonary embolism or deep vein thrombosis within the previous 6 months
- •Diagnosis of pulmonary edema
- •Diagnosis of congestive heart failure (uncontrolled)
- •Diagnosis of chronic kidney disease with renal failure
- •Diagnosis of epilepsy
- •Subjects with poorly controlled asthma
- •Any condition where increased venous and lymphatic return is undesirable
- •Women who are pregnant, planning a pregnancy or nursing at study entry
- •Participation in any clinical trial of an investigational substance or device during the past 30 days
研究组 & 干预措施
Dayspring Active Wearable Compression Device
The Dayspring Active Wearable Compression Device is an FDA cleared calibrated active gradient pressure full-arm compression garment that is segmental and programmable and applies controlled sequential pressure from the distal to proximal-end of the limb in a cyclic manner.
干预措施: Crossover Device (PCD or Dayspring - alternate to first group) (Device)
Advanced Pneumatic Compression Device
A commercially available advanced pneumatic compression device that is FDA-cleared for the same indication for use as the Dayspring Wearable Compression Device.
干预措施: Crossover Device (PCD or Dayspring - alternate to first group) (Device)
结局指标
主要结局
Arm Volume Maintenance or Improvement
时间窗: 1 month
Limb volume measurement is performed by using a calibrated tape measure to measure circumference from the wrist and the ulnar styloid process and at 4cm increments to the axilla. Measurements to be taken for both upper extremities. Volume is calculated based on cylindrical segment analysis. The outcome measure is assessed as a difference or change from baseline to month 1
LYMQOL (LYMphedema Quality of Life)
时间窗: 1 month
The Lymphedema Quality of Life Questionnaire (LYMQOL), a validated disease-specific QoL tool, is also administered at baseline and month 1. Overall QoL is scored on a single item by the patient on a scale of 1-10. The outcome measure is assessed as a difference or change from baseline LYMQOL at day zero and month 1
次要结局
- Therapy adherence tracking(1 month)
- Safety/AEs(1 month)
- Patient survey on preference(1 month)